The PRIMA miniaturized, wireless, subretinal implant to restore vision in patients affected by retinal dystrophies has received French authorization to begin a feasibility study in human patients with advanced dry age-related macular degeneration, according to a Pixium Vision press release.
The study, which will enroll five patients, was approved by the French regulatory agency Agence Nationale de Sécurité du Médicament et des Produits de Santé. It will evaluate the tolerance of PRIMA and demonstrate the central visual perception in patients who have lost sight due
Uncategorized